Skip to main content

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma

Cancer Immunology, Immunotherapy volume 58, pages 1351–1353 (2009)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

39,95 €

Price includes VAT (Finland)

Fig. 1

References

  1. Young NS (2005) Chapter 34. Pure red cell aplasia (Chapter). In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT (eds) Williams hematology, 7th edn. McGraw-Hill, New York. http://www.accessmedicine.com/content.aspx?aID=2140349

  2. Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864–872

    Article  PubMed  CAS  Google Scholar 

  3. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736

    Article  PubMed  CAS  Google Scholar 

  4. Kapadia D, Fong L (2005) CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol 23:8926–8928

    Article  PubMed  CAS  Google Scholar 

  5. Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043–6053

    Article  PubMed  CAS  Google Scholar 

  6. Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688

    Article  PubMed  CAS  Google Scholar 

  7. Young NS, Abkowitz JL, Luzzatto L (2000) New insights into the pathophysiology of acquired cytopenias. Hematology Am Soc Hematol Educ Program 18–38

  8. Rossert J, Macdougall I, Casadevall N (2005) Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: Multiple options. Nephrol Dial Transplant 20(Suppl 4):iv23–iv26

    Article  PubMed  Google Scholar 

  9. Mouthon L, Guillevin L, Tellier Z (2005) Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 4:264–269

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Chicago, 5841 S. Maryland Ave., TW055, Chicago, IL, 60637, USA

    Ilyssa O. Gordon, Jerome Dickstein & Thomas F. Gajewski

  2. Department of Medicine, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL, 60637, USA

    Takisha Wade & Thomas F. Gajewski

  3. Bristol-Myers Squibb, Wallingford, CT, USA

    Kevin Chin

Authors
  1. Ilyssa O. Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takisha Wade
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jerome Dickstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas F. Gajewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jerome Dickstein or Thomas F. Gajewski.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gordon, I.O., Wade, T., Chin, K. et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 58, 1351–1353 (2009). https://doi.org/10.1007/s00262-008-0627-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-008-0627-x

Keywords

  • Sorafenib
  • Sentinel Lymph Node Biopsy
  • Metastatic Melanoma
  • Germinal Center
  • Ipilimumab